Playing catch-up with J&J, Sanofi taps Blackstone for $300M to fund pivotal trial of subcutaneous Sarclisa

Sanofi has turned to Blackstone Life Sciences for help developing a subcutaneous formulation of multiple myeloma drug Sarclisa. Blackstone is putting up $300 million to fund development of the formulation in return for a chance to receive royalties on future subcutaneous sales.